「¹¹C」胆碱PET/CT作为原发性甲状旁腺功能亢进一线成像的成本效益
本研究基于前瞻性试验数据开展成本-效用分析,比较原发性甲状旁腺功能亢进中定位甲状旁腺腺瘤的两种成像策略。决策树模型显示,一线「¹¹C」胆碱PET/CT总成本为€10,394、QALY增益16.66,而现行标准路径成本€10,907、QALY 16.63,增量成本-效用比为-€18,846/QALY,提示其具成本效益优势。
要点
- 「¹¹C」胆碱PET/CT较现行标准路径成本更低且QALY更高,ICUR为-€18,846/QALY。
- 成本效益最敏感因素为「¹¹C」胆碱PET/CT的成本变化。
- 模型为特定中心视角,其他中心可借助开源R脚本按本地数据确定最优策略。
核心结论
- 该中心特异性模型支持将一线「¹¹C」胆碱PET/CT作为定位甲状旁腺腺瘤的成本效益策略,但取决于「¹¹C」胆碱PET/CT的成本。
研究设计与样本
- 基于前瞻性试验数据,对五种成像方式(一线cUS与MIBI SPECT/CT,二线「¹¹C」胆碱PET/CT、「¹¹C」甲硫氨酸PET/CT和4D-CT)进行诊断准确性评估。
- 在R-studio构建决策树模型,比较逐步升级路径与仅使用一种二线成像的路径,采用中心特异性视角、24年时间跨度计算€/QALY,并行概率蒙特卡洛分析及一维/二维敏感性分析。
主要发现
- 「¹¹C」胆碱PET/CT总成本€10,394,QALY增益16.66。
- 现行标准cUS+MIBI SPECT/CT必要时二线成像成本€10,907,QALY 16.63。
- 「¹¹C」胆碱PET/CT的ICUR为-€18,846/QALY,显示以更低成本获得更大效果的优势。
- 敏感性分析显示成本效益对「¹¹C」胆碱PET/CT成本变化最敏感。
关键数值与推荐
- 「¹¹C」胆碱PET/CT:总成本€10,394,QALY 16.66。
- cUS+MIBI SPECT/CT必要时二线成像:总成本€10,907,QALY 16.63。
- ICUR为-€18,846/QALY。
临床怎么用
- 在「¹¹C」胆碱PET/CT成本适宜的中心,可考虑将其作为原发性甲状旁腺功能亢进定位甲状旁腺腺瘤的一线成像策略。
- 其他中心可利用所提供开源R脚本,结合本地诊断准确性与成本数据确定最优成像策略。
局限性
- 成本效益结论取决于「¹¹C」胆碱PET/CT的成本,且模型为中心特异性视角。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We performed a cost-utility analysis, using prospectively gathered trial data, comparing two imaging strategies for localizing parathyroid adenomas in primary hyperparathyroidism (pHPT) to determine the most cost-effective approach. Additionally, we provide customizable open-source R-script enabling other centres to identify their optimal imaging strategy based on local diagnostic accuracy and cost data. METHODS: An evaluation of the diagnostic accuracy was performed for five imaging modalities: first-line cervical ultrasound (cUS) and [99mTc]Tc-methoxy isobutyl isonitrile-single-photon-emission-computed- tomography/computed-tomography (MIBI SPECT/CT), and second-line [¹¹C]choline positron-emitting-tomography/CT (PET/CT), [¹¹C]methionine PET/CT, and 4 dimensional (4D)-CT. A decision-tree-model, constructed in R-studio, compared two diagnostic pathways: (1) The comparator pathway: a stepwise approach starting with cUS and MIBI SPECT/CT escalating to one of three second-line imaging modalities if needed, and (2) use of only one second-line imaging. Costs and quality-adjusted life years (QALYs) were evaluated across pathways, and cost-utility ratios (€/QALY) were calculated for a centre specific perspective with a 24-year time horizon based on life expectancy. In addition, to test the joint parameter uncertainty of the model, a probabilistic Monte-Carlo analysis was performed. One- and two-way sensitivity analyses were conducted to assess model robustness. RESULTS: [¹¹C]choline PET/CT had a total costs of €10,394 and a QALY gain of 16.66. In contrast, the current standard, cUS + MIBI SPECT/CT with, when necessary, second-line imaging, costs €10,907 and yields 16.63 QALYs. The incremental cost-utility ratio (ICUR) for [¹¹C]choline PET/CT was -€18,846/QALY, indicating dominance with lower cost and greater effectiveness. Sensitivity analyses showed that cost-effectiveness was most sensitive to variations in costs of [¹¹C]choline PET/CT. CONCLUSION: This centre-specific model supports first-line [¹¹C]choline PET/CT as a cost-effective first-line strategy for localization of parathyroid adenomas, depending on [¹¹C]choline PET/CT costs. Additionally, the provided cost-utility model, enables other centres to determine their optimal imaging strategy.
引用
- Schouw HM, Melis J, Lutterop JW, et al. Cost-effectiveness of [¹¹C]Choline PET/CT as first-line imaging in primary hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2026. PMID: 41661253. doi:10.1007/s00259-025-07746-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。